# Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

> **NCT04798287** · — · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 105711 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tofacitinib
- **DRUG:** TNF Inhibitor

## Key facts

- **NCT ID:** NCT04798287
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-10
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-05-16
- **Target enrollment:** 105711 (ACTUAL)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04798287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04798287, "Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04798287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*